Systematic Review: Charged-Particle Radiation Therapy for Cancer

Terasawa, Teruhiko; Dvořák, Tomáš; Ip, Stanley; Raman, Gowri; Lau, Joseph; Trikalinos, Thomas A

doi:10.7326/0003-4819-151-8-200910200-00145

Cited by 90 publications

(76 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The color of the mixture turned purplered from pale yellow within 5 min and the formation of gold nanoparticles was characterized by UV-Visible spectroscopy. Full details of synthesis, characterization and stability studies of EGCg-AuNP in biologically relevant solutions (10% NaCl, 0.5% cysteine, 0.2 M histidine, 0.5% HSA and different pH buffers) (7,9) are provided in SI Text (15).…”

Section: Discussionmentioning

confidence: 99%

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Shukla

Chanda

Zambre

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

232

183

View full text Add to dashboard Cite

Systemic delivery of therapeutic agents to solid tumors is hindered by vascular and interstitial barriers. We hypothesized that prostate tumor specific epigallocatechin-gallate (EGCg) functionalized radioactive gold nanoparticles, when delivered intratumorally (IT), would circumvent transport barriers, resulting in targeted delivery of therapeutic payloads. The results described herein support our hypothesis. We report the development of inherently therapeutic gold nanoparticles derived from the Au-198 isotope; the range of the 198 Au β-particle (approximately 11 mm in tissue or approximately 1100 cell diameters) is sufficiently long to provide cross-fire effects of a radiation dose delivered to cells within the prostate gland and short enough to minimize the radiation dose to critical tissues near the periphery of the capsule. The formulation of biocompatible 198 AuNPs utilizes the redox chemistry of prostate tumor specific phytochemical EGCg as it converts gold salt into gold nanoparticles and also selectively binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells. Pharmacokinetic studies in PC-3 xenograft SCID mice showed approximately 72% retention of 198 AuNP-EGCg in tumors 24 h after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 d demonstrating significant inhibition of tumor growth compared to controls. This innovative nanotechnological approach serves as a basis for designing biocompatible target specific antineoplastic agents. This novel intratumorally injectable 198 AuNP-EGCg nanotherapeutic agent may provide significant advances in oncology for use as an effective treatment for prostate and other solid tumors.nanoradiotherapy | tumor metastases | localized therapy | polyphenols | cellular targeting R ecent data have confirmed that the incidence of prostate cancer is the highest among all estimated new cancer cases in American males, nearly double that of lung cancer (1). Globally, prostate cancer continues to be the second leading cause of cancer-related death in men (1). A detailed study involving 77,000 North Americans has shown that 10 y of regular prostate specific antigen (PSA) screening did not save a significant number of lives (2). Therefore, developments of new therapeutic protocols that provide effective control of the growth and propagation of prostate tumors have gained considerable clinical significance in the care and treatment of prostate cancer patients (3). The latest clinical trials on human prostate cancer patients using various experimental drugs further attest that shrinking prostate tumor sizes led to more than doubled survival in 70-80% of patients with aggressive cancers (3). Although a plethora of therapeutic approaches, which include utility of cytotoxic drugs (paclitaxel, estramustine, carboplatin, and doxorubicin) are currently in clinical practice, unfortunately, none of these chemotherapeutic agents offer a clinically efficient, affordable, and toxicologically safe regimen...

show abstract

Section: Discussionmentioning

confidence: 99%

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Shukla

Chanda

Zambre

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

232

183

View full text Add to dashboard Cite

show abstract

“…Published clinical series suggest some clinical benefit from CPRT in a number of conditions when compared with current conventional X-ray techniques 11. Despite the fact that the existing evidence is not at the highest level (2011 Oxford CEBM Levels of Evidence (Introductory Document), Oxford Centre for Evidence-Based Medicine: http://www.cebm.net/index.aspx?o=5653), the available clinical results have important implications in that they may influence the judgment of individual clinicians and could disturb clinical equipoise, while also possibly influencing patients’ views.…”

Section: Clinical and Scientific Considerationsmentioning

confidence: 99%

Position statement on ethics, equipoise and research on charged particle radiation therapy

Sheehan¹,

Timlin²,

Peach³

et al. 2013

J Med Ethics

View full text Add to dashboard Cite

The use of charged-particle radiation therapy (CPRT) is an increasingly important development in the treatment of cancer. One of the most pressing controversies about the use of this technology is whether randomised controlled trials are required before this form of treatment can be considered to be the treatment of choice for a wide range of indications. Equipoise is the key ethical concept in determining which research studies are justified. However, there is a good deal of disagreement about how this concept is best understood and applied in the specific case of CPRT. This report is a position statement on these controversies that arises out of a workshop held at Wolfson College, Oxford in August 2011. The workshop brought together international leaders in the relevant fields (radiation oncology, medical physics, radiobiology, research ethics and methodology), including proponents on both sides of the debate, in order to make significant progress on the ethical issues associated with CPRT research. This position statement provides an ethical platform for future research and should enable further work to be done in developing international coordinated programmes of research.

show abstract

“…Currently there are seven proton beam facilities running in the USA and at least there are four more under construction. 17 With the emergence of new facilities, along with new surgeons, radiation oncologists, and physicists treating this rare disease, it has become imperative that accurate and reproducible tools be used in the planning process to ensure continued high success rates. Errors are possible during the surgical, planning, and/or treatment process, and hence methods to continually develop our standards of practice are essential.…”

Section: Introductionmentioning

confidence: 99%

Fundus image fusion in EYEPLAN software: An evaluation of a novel technique for ocular melanoma radiation treatment planning

et al. 2010

View full text Add to dashboard Cite

Purpose:The purpose of this study is to evaluate a novel approach for treatment planning using digital fundus image fusion in EYEPLAN for proton beam radiation therapy ͑PBRT͒ planning for ocular melanoma. The authors used a prototype version of EYEPLAN software, which allows for digital registration of high-resolution fundus photographs. The authors examined the improvement in tumor localization by replanning with the addition of fundus photo superimposition in patients with macular area tumors. Methods:The new version of EYEPLAN ͑v3.05͒ software allows for the registration of fundus photographs as a background image. This is then used in conjunction with clinical examination, tantalum marker clips, surgeon's mapping, and ultrasound to draw the tumor contour accurately. In order to determine if the fundus image superimposition helps in tumor delineation and treatment planning, the authors identified 79 patients with choroidal melanoma in the macular location that were treated with PBRT. All patients were treated to a dose of 56 GyE in four fractions. The authors reviewed and replanned all 79 macular melanoma cases with superimposition of pretreatment and post-treatment fundus imaging in the new EYEPLAN software. For patients with no local failure, the authors analyzed whether fundus photograph fusion accurately depicted and confirmed tumor volumes as outlined in the original treatment plan. For patients with local failure, the authors determined whether the addition of the fundus photograph might have benefited in terms of more accurate tumor volume delineation. Results: The mean follow-up of patients was 33.6Ϯ 23 months. Tumor growth was seen in six eyes of the 79 macular lesions. All six patients were marginal failures or tumor miss in the region of dose fall-off, including one patient with both in-field recurrence as well as marginal. Among the six recurrences, three were managed by enucleation and one underwent retreatment with proton therapy. Three patients developed distant metastasis and all three patients have since died. The replanning of six patients with their original fundus photograph superimposed showed that in four cases, the treatment field adequately covered the tumor volume. In the other two patients, the overlaid fundus photographs indicated the area of marginal miss. The replanning with the fundus photograph showed improved tumor coverage in these two macular lesions. For the remaining patients without local failure, replanning with fundus photograph superimposition confirmed the tumor volume as drawn in the original treatment plan. Conclusions: Local control was excellent in patients receiving 56 GyE of PBRT for uveal melanomas in the macular region, which traditionally can be more difficult to control. Posterior lesions are better defined with the additional use of fundus image since they can be difficult to mark surgically. In one-third of treatment failing patients, the superposition of the fundus photograph would have clearly allowed improved localization of tumor. The current practice s...

show abstract

Systematic Review: Charged-Particle Radiation Therapy for Cancer

Abstract: Evidence on the comparative effectiveness and safety of charged-particle radiation therapy in cancer is needed to assess the benefits, risks, and costs of treatment alternatives.

Cited by 90 publications

References 53 publications

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Position statement on ethics, equipoise and research on charged particle radiation therapy

Fundus image fusion in EYEPLAN software: An evaluation of a novel technique for ocular melanoma radiation treatment planning

Contact Info

Product

Resources

About

Systematic Review: Charged-Particle Radiation Therapy for Cancer

Abstract: Evidence on the comparative effectiveness and safety of charged-particle radiation therapy in cancer is needed to assess the benefits, risks, and costs of treatment alternatives.

Cited by 90 publications

References 53 publications

Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancer

Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancer

Position statement on ethics, equipoise and research on charged particle radiation therapy

Fundus image fusion in EYEPLAN software: An evaluation of a novel technique for ocular melanoma radiation treatment planning

Contact Info

Product

Resources

About

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer